VSM Wealth Advisory LLC Invests $61,000 in Elevance Health, Inc. $ELV

VSM Wealth Advisory LLC purchased a new stake in Elevance Health, Inc. (NYSE:ELV) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 156 shares of the company’s stock, valued at approximately $61,000.

Several other large investors also recently made changes to their positions in the business. Nuveen LLC acquired a new position in shares of Elevance Health during the 1st quarter valued at $789,943,000. Sanders Capital LLC raised its position in Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock valued at $2,265,773,000 after purchasing an additional 1,152,440 shares during the period. Vanguard Group Inc. increased its position in shares of Elevance Health by 3.2% during the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company’s stock worth $8,890,419,000 after acquiring an additional 704,790 shares during the last quarter. Orbis Allan Gray Ltd lifted its stake in shares of Elevance Health by 31.4% in the first quarter. Orbis Allan Gray Ltd now owns 2,849,173 shares of the company’s stock worth $1,239,276,000 after acquiring an additional 680,228 shares in the last quarter. Finally, Boston Partners boosted its holdings in Elevance Health by 241.3% in the first quarter. Boston Partners now owns 856,737 shares of the company’s stock valued at $372,039,000 after purchasing an additional 605,689 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Performance

Shares of ELV stock opened at $324.64 on Wednesday. The company has a market cap of $72.15 billion, a P/E ratio of 13.27, a PEG ratio of 1.23 and a beta of 0.60. The business has a 50 day moving average of $330.37 and a two-hundred day moving average of $339.63. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.03 by $1.00. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The business had revenue of $50.09 billion for the quarter, compared to analysts’ expectations of $49.26 billion. During the same period in the prior year, the firm earned $8.37 EPS. The business’s quarterly revenue was up 12.0% on a year-over-year basis. As a group, analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 19th. Investors of record on Friday, December 5th will be given a $1.71 dividend. This represents a $6.84 annualized dividend and a yield of 2.1%. The ex-dividend date is Friday, December 5th. Elevance Health’s dividend payout ratio (DPR) is currently 27.96%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ELV shares. Mizuho dropped their price objective on Elevance Health from $420.00 to $400.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd. Weiss Ratings restated a “sell (d+)” rating on shares of Elevance Health in a research note on Monday. Cowen reaffirmed a “buy” rating on shares of Elevance Health in a report on Thursday, October 23rd. Morgan Stanley raised their price objective on shares of Elevance Health from $316.00 to $359.00 and gave the stock an “equal weight” rating in a report on Tuesday, October 14th. Finally, Barclays reduced their price target on shares of Elevance Health from $395.00 to $385.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 22nd. Twelve investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Elevance Health has a consensus rating of “Hold” and a consensus price target of $397.33.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.